Clinical trial
NeoVax With Nivolumab in Patients With Ovarian Cancer
NCT04024878 is registered in ClinicalTrials.gov with Dana-Farber Cancer Institute as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- NeoVax With Nivolumab in Patients With Ovarian Cancer
- Lead sponsor
- Dana-Farber Cancer Institute
- Phase
- Phase 1
- Overall status
- Active, not recruiting
- Start date
- November 20, 2020
- Completion date
- April 30, 2029
- Enrollment
- 22 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
ovarian cancer